<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Allergy Clin Immunol Glob</journal-id><journal-id journal-id-type="iso-abbrev">J Allergy Clin Immunol Glob</journal-id><journal-id journal-id-type="pmc-domain-id">4505</journal-id><journal-id journal-id-type="pmc-domain">jacig</journal-id><journal-title-group><journal-title>The Journal of Allergy and Clinical Immunology: Global</journal-title></journal-title-group><issn pub-type="epub">2772-8293</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11585680</article-id><article-id pub-id-type="pmcid-ver">PMC11585680.1</article-id><article-id pub-id-type="pmcaid">11585680</article-id><article-id pub-id-type="pmcaiid">11585680</article-id><article-id pub-id-type="pmid">39583037</article-id><article-id pub-id-type="doi">10.1016/j.jacig.2024.100348</article-id><article-id pub-id-type="pii">S2772-8293(24)00144-9</article-id><article-id pub-id-type="publisher-id">100348</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original article</subject></subj-group></article-categories><title-group><article-title>Associations of aeroallergen testing with reduced oral corticosteroid bursts among adults with asthma</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Gleeson</surname><given-names initials="PK">Patrick K.</given-names></name><degrees>MD, MSCE</degrees><email>patrick.gleeson@pennmedicine.upenn.edu</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Morales</surname><given-names initials="KH">Knashawn H.</given-names></name><degrees>ScD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Buckey</surname><given-names initials="TM">Timothy M.</given-names></name><degrees>MD, MBE</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Fadugba</surname><given-names initials="OO">Olajumoke O.</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Apter</surname><given-names initials="AJ">Andrea J.</given-names></name><degrees>MD, MSc, MA</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Christie</surname><given-names initials="JD">Jason D.</given-names></name><degrees>MD, MSCE</degrees><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Himes</surname><given-names initials="BE">Blanca E.</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><aff id="aff1"><label>a</label>Section of Allergy and Immunology, Division of Pulmonary, Allergy and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa</aff><aff id="aff2"><label>b</label>Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa</aff><aff id="aff3"><label>c</label>Division of Pulmonary, Allergy and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>Corresponding author: Patrick K. Gleeson, MD, MSCE, Penn Allergy and Immunology University City, 3rd Floor, 3737 Market St, Philadelphia, PA 19104. <email>patrick.gleeson@pennmedicine.upenn.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>17</day><month>10</month><year>2024</year></pub-date><volume>4</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">474379</issue-id><elocation-id>100348</elocation-id><history><date date-type="received"><day>12</day><month>3</month><year>2024</year></date><date date-type="rev-recd"><day>21</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>20</day><month>9</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>10</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>24</day><month>11</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-02 13:25:27.340"><day>02</day><month>12</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 The Authors</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="preprint" xml:lang="en" xlink:title="research-article" vol="5" elocation-id="2024.01.29.24301962" journal-id="medRxiv" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC10863005"><article-title>
Benefits of Aeroallergen Testing on Oral Corticosteroid Bursts in Adults with Asthma
</article-title><date><day>30</day><month>1</month><year>2024</year></date><elocation-id>2024.01.29.24301962</elocation-id><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2024.01.29.24301962</pub-id><pub-id pub-id-type="pmcid">PMC10863005</pub-id><pub-id pub-id-type="pmid">38352545</pub-id></related-article><abstract id="abs0010"><sec><title>Background</title><p>Aeroallergen testing can improve precision care for persistent asthma. How testing benefits diverse populations of adults with asthma and the importance of the aeroallergen sensitization and test modality used remain poorly understood.</p></sec><sec><title>Objective</title><p>We evaluated whether aeroallergen testing was associated with a reduction in oral corticosteroid (OCS) bursts.</p></sec><sec><title>Methods</title><p>We used electronic health record data to conduct a retrospective cohort study of adults with asthma who were prescribed an inhaled corticosteroid and had an allergy/immunology visit in a large health system between January 1, 2017, and June 30, 2022. We used negative binomial regression models to evaluate whether testing was associated with fewer OCS bursts in the 12-month period after an initial visit among all patients and those without chronic obstructive pulmonary disease (COPD) and smoking histories. We then repeated these analyses while considering effects of sensitization to aeroallergen categories and whether the testing was via skin prick or serum-specific IgE.</p></sec><sec><title>Results</title><p>A total of 684 (48.4%) of 1,412 patients underwent testing. Testing was not associated with fewer bursts overall (incidence rate ratio [IRR]&#160;= 0.84 vs no testing, <italic toggle="yes">P</italic>&#160;= .08), but it was among never smokers without COPD (461 of 927 tested, IRR&#160;= 0.69, <italic toggle="yes">P</italic>&#160;= .005). Among never smokers without COPD, sensitization to 5-7 aeroallergen categories (IRR&#160;= 0.57 vs no test, <italic toggle="yes">P</italic>&#160;= .003) and receipt of skin prick tests (IRR&#160;= 0.58 vs no test, <italic toggle="yes">P</italic>&#160;&lt; .0005) were associated with fewer bursts.</p></sec><sec><title>Conclusion</title><p>Aeroallergen testing was associated with reduced OCS bursts among adults with asthma who were never smokers without COPD. This association varied according to aeroallergen sensitization and test modality used.</p></sec></abstract><kwd-group id="kwrds0010"><title>Key words</title><kwd>Asthma</kwd><kwd>aeroallergen testing</kwd><kwd>asthma exacerbations</kwd><kwd>electronic health record</kwd><kwd>epidemiology</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta><def-list><title>Abbreviations used</title><def-item><term id="kwrd0040">BMI</term><def><p>Body mass index</p></def></def-item><def-item><term id="kwrd0050">COPD</term><def><p>Chronic obstructive pulmonary disease</p></def></def-item><def-item><term id="kwrd0060">COVID-19</term><def><p>Coronavirus disease 2019</p></def></def-item><def-item><term id="kwrd0070">ED</term><def><p>Emergency department</p></def></def-item><def-item><term id="kwrd0080">EHR</term><def><p>Electronic health record</p></def></def-item><def-item><term id="kwrd0090">ICD-10</term><def><p>International Classification of Diseases, Tenth Revision</p></def></def-item><def-item><term id="kwrd0100">ICS</term><def><p>Inhaled corticosteroid</p></def></def-item><def-item><term id="kwrd0110">IRR</term><def><p>Incidence rate ratio</p></def></def-item><def-item><term id="kwrd0120">LABA</term><def><p>Long-acting &#946;-agonist</p></def></def-item><def-item><term id="kwrd0130">LAMA</term><def><p>Long-acting muscarinic antagonist</p></def></def-item><def-item><term id="kwrd0140">OCS</term><def><p>Oral corticosteroid</p></def></def-item><def-item><term id="kwrd0150">SPT</term><def><p>Skin prick test</p></def></def-item></def-list></front><body><p id="p0010">Asthma is a common chronic disease in adults and a major public health burden in the United States.<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref> A&#160;key component of asthma care is to reduce symptoms and exacerbations by addressing modifiable risk factors, including aeroallergen exposure in sensitized patients.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> Pollens, dust mite, cat, dog, and molds are common allergens and important asthma triggers.<xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref> Addressing allergic asthma triggers is beneficial in adults with asthma; most are sensitized to aeroallergens, and aeroallergen exposure is nearly universal in US homes.<xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref> In studies of adults with asthma, aeroallergen testing with allergen avoidance education improved patients&#8217; awareness of perceived asthma triggers and lung function<xref rid="bib25" ref-type="bibr"><sup>24</sup></xref> and complemented asthma self-management.<xref rid="bib26" ref-type="bibr"><sup>25</sup></xref> National Heart, Lung, and Blood Institute&#8211;led online focus groups of people with asthma that explored patients&#8217; values and priorities related to their asthma found that most patients took steps to mitigate indoor allergen exposure.<xref rid="bib27" ref-type="bibr"><sup>26</sup></xref> Thus, testing aligns with patients&#8217; strategies to reduce asthma symptoms.</p><p id="p0015">The US clinical guidelines recommend aeroallergen testing for patients with persistent asthma, which is defined as asthma requiring step 2 or higher treatment to maintain control; and the preferred controller treatment at step 2 is an inhaled corticosteroid (ICS)-containing treatment.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib27" ref-type="bibr"><sup>26</sup></xref> However, allergen mitigation may be difficult or costly, and the benefit of testing large numbers of adults with asthma in a real-life setting has not been well studied. In prior work, we found that among 1,789 adults with asthma who established outpatient care in a large health system, who were prescribed an ICS, and who underwent aeroallergen testing, receipt of oral corticosteroid (OCS) bursts was reduced in the 12-month period after testing compared with before.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> Consistent with the clinical focus of providers, testing was more often performed in the context of asthma subspecialty clinics, specifically allergy/immunology and pulmonary, rather than in primary care (odds ratios of 91.3 and 7.1 vs primary care, respectively). However, that study was unable to determine whether improved outcomes were due to allergy testing and testing-based management versus other interventions that may have occurred during specialist visits. Moreover, although many patients with asthma have smoking histories and/or comorbid chronic obstructive pulmonary disease (COPD), 2 studies that evaluated the benefits of aeroallergen testing limited or excluded these patients.<xref rid="bib25" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="bib26" ref-type="bibr"><sup>25</sup></xref> Furthermore, although patients with allergic sensitization to aeroallergens may be expected to benefit the most from testing, this is not well studied. Finally, prior investigations have not evaluated the relative benefits of testing via skin prick tests (SPTs) or serum-specific IgE tests among adults with asthma.</p><p id="p0020">In this study, we sought to determine, among adults with asthma who had an allergy/immunology visit, whether undergoing guideline-concordant aeroallergen testing was associated with fewer OCS bursts after the visit compared with patients who did not undergo testing. We then considered whether the association of testing with OCS bursts differed for patients who did not have COPD and who were never smokers; and whether the association varied according to aeroallergen sensitization or the test modality.</p><sec id="sec1"><title>Methods</title><sec id="sec1.1"><title>Study design</title><p id="p0025">We conducted a retrospective cohort study of adults with asthma using electronic health record (EHR) data from Penn Medicine, a large, diverse health system that serves the greater Philadelphia area, from encounters dated January 1, 2015, to June 30, 2023. The University of Pennsylvania institutional review board approved our study.</p></sec><sec id="sec1.2"><title>Study population</title><p id="p0030">We obtained patient-level data and clinical notes for adults (ie, age &#8805;18 years) who had at least one encounter with an International Classification of Diseases, Tenth Revision (ICD-10), code for asthma (J45&#8727;) in any of their records; received an ICS prescription from January 1, 2016, to June 30, 2023; and had 2 or more outpatient visits at Penn&#8217;s primary allergy/immunology clinic from January 1, 2017, to June 30, 2023, for which the index visit occurred on or before June 30, 2022. We chose a 2-visit threshold to ensure that all patients had established allergy/immunology care. Patient-level data included age at the index visit (categorized into 5 levels); sex; race (using EHR categories); ethnicity (ie, Hispanic or Latino status); insurance (categorized as commercial, Medicaid, or Medicare); body mass index (BMI in kg/m<sup>2</sup>, categorized into the 5 levels used by the Centers for Disease Control and Prevention<xref rid="bib28" ref-type="bibr"><sup>27</sup></xref>); smoking category (never, former, or current); and chronic rhinitis (defined as having any ICD-10 code of J30&#8727; or J31&#8727;).</p></sec><sec id="sec1.3"><title>Timeline of observations included</title><p id="p0035"><xref rid="fig1" ref-type="fig">Fig 1</xref> displays timelines of data considered. We chose January 1, 2017, as the date of the earliest possible index visit because in our health system, emergency department (ED) and hospitalization encounter data from some hospitals in 2015 are missing from the data warehouse, whereas encounter data from January 1, 2016, onward is complete.<fig id="fig1" position="float" orientation="portrait"><label>Fig 1</label><caption><p><bold>A,</bold> Overall study period. Shown are observation periods for the index visit, aeroallergen testing after the index visit, counting of OCS bursts after the index visit, and additional lookback period to confirm that aeroallergen testing was not performed. <bold>B,</bold> Individual-level study period. This timeline is centered on the index visit date for each patient. Shown are the 90-day observation period for aeroallergen testing and step-up therapy after the index visit, the 12-month observation periods for OCS bursts before and after the index visit, and the lookback period to confirm that aeroallergen testing was not performed.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="sec1.4"><title>Asthma exacerbation measures</title><p id="p0040">We selected 3 variables to represent asthma exacerbations during the 12-month period before the index visit: OCS bursts, ED visits, and hospitalizations. OCS bursts were categorized into 4 groups: counts of 0, 1, 2-3, and 4 or more; and ED visits and hospitalizations into 2 groups each: counts of 0, and 1 or more. The outcome of OCS bursts in the 12-month period after the index visit was modeled as count data. Definitions for OCS bursts, ED visits, and hospitalizations are described in the Methods section of the Online Repository available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.jaci-global.org" id="intref0010">www.jaci-global.org</ext-link>, and lists of ICD-10 codes and chief complaints that were used to deem ED visits and hospitalizations as asthma related are provided in <xref rid="appsec1" ref-type="sec">Table E1</xref>, also available in the Online Repository.</p></sec><sec id="sec1.5"><title>Aeroallergen testing data</title><p id="p0045">We defined aeroallergen testing as receipt of any SPT or serum-specific IgE test to tree, grass, weed, dust mite, cat, dog, or mold that was recorded in the EHR as structured data, as previously described.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> More details are available in the Methods section of the Online Repository. We chose a 90-day threshold for testing after the index visit so it could occur within the 3-month follow-up interval that is consistent with guideline care.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> We considered 2 definitions for testing after the index visit. The first was a binary variable of no testing or any testing. The second was a 3-level test modality variable of (1) no testing, (2) receipt of SPTs (ie, with or without serum-specific IgE tests), or (3) receipt of only serum-specific IgE tests.</p></sec><sec id="sec1.6"><title>Aeroallergen sensitization data</title><p id="p0050">We defined sensitization to aeroallergens as previously described.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> We categorized test results into 7 categories of tree, grass, weed, dust mite, cat, dog, and mold,<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> and considered results for patients who had results in all 7 categories. We then created a 3-level aeroallergen sensitization variable of no testing, sensitization to 1-4 categories, or sensitization to 5-7 categories.</p></sec><sec id="sec1.7"><title>Inhaler data</title><p id="p0055">We identified inhaler prescription data during the 12-month period before the index visit and categorized these into 3 groups: (1) no ICS-containing prescriptions, (2) ICS prescriptions only, (3) any ICS/long-acting &#946;-agonist (LABA) prescriptions, and (4) any ICS/LABA plus long-acting muscarinic antagonist (LAMA) prescriptions. We also identified inhaler prescription data in the 90-day period after the index visit to determine whether step-up therapy occurred. More details are provided in the Methods section in the Online Repository.</p></sec><sec id="sec1.8"><title>COPD</title><p id="p0060">We defined COPD as having any ICD-10 code of J41&#8727;, J42&#8727;, J43&#8727;, or J44&#8727;; and prescription of any of LAMA, LABA, or LABA/LAMA inhaler formulations from January 1, 2016, to June 30, 2023. Lists of these inhalers are shown in <xref rid="appsec1" ref-type="sec">Table E2</xref> in the Online Repository available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.jaci-global.org" id="intref0015">www.jaci-global.org</ext-link>.</p></sec><sec id="sec1.9"><title>Documentation of likely reasons that providers did not perform testing, performed testing, and performed serum-specific IgE testing</title><p id="p0065">An allergy/immunology specialist performed EHR chart review for 50 patients who were categorized as not undergoing testing to determine the likely reason that a test was not performed. A&#160;second reviewer who was an allergy/immunology fellow reviewed the same 50 charts, and for any disagreements, the 2 reviewers reached consensus. In addition, the specialist performed chart review for 50 patients with aeroallergen testing to identify the likely reason that it was performed; and for 50 patients with serum-specific IgE testing to identify the likely reason that it was performed (ie, instead of SPTs). Details are provided in the Methods section of the Online Repository.</p></sec><sec id="sec1.10"><title>Statistical analysis</title><p id="p0070">Stata 16.1 was used to perform statistical analysis. We evaluated bivariate associations of patient demographic factors (eg, age, sex, race, and ethnicity), insurance, BMI, smoking, COPD, chronic rhinitis, inhaler category, and exacerbation measures in the 12-month period before the index visit, and receipt of step-up therapy after the index visit with testing versus no testing by Pearson chi-square tests. For the primary analysis, we created a multivariable negative binomial regression model with OCS burst count in the 12-month period after the index visit as the outcome, the binary testing variable as the exposure, and the same variables as in the bivariate associations, except for step-up therapy, included as covariates. We assessed collinearity among the independent variables by computing their variance inflation factors. We repeated the model creation in 3 secondary analyses after (1) restricting the dataset to patients whose index visits and 90-day postvisit periods occurred earlier than Philadelphia&#8217;s coronavirus disease 2019 (COVID-19) lockdown date of March 17, 2020; (2) excluding patients with COPD; and (3) excluding both patients with COPD and current or former smokers.</p><p id="p0075">Among patients who either did not undergo testing, or who underwent testing to 7 aeroallergen categories and had sensitization to at least one category, we repeated the primary analysis and each of the 3 secondary analyses using the 3-level aeroallergen sensitization variable.</p><p id="p0080">We then evaluated the same bivariate associations of patient factors with receipt of any SPTs versus only serum-specific IgE tests by Pearson chi-square tests. Finally, we repeated each of the 4 primary and secondary analyses using the 3-level test modality variable.</p></sec></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Patient characteristics</title><p id="p0085">Of 1,412 adults with asthma who appeared to be eligible for testing according to guidelines, 684 (48.4%) underwent testing within 90 days of their index visits, and 728 (51.6%) did not undergo testing. A&#160;total of 923 (65.4%) of 1,412 also had an internal medicine or family medicine visit, and 453 (32.1%) of 1,412 also had a pulmonary visit. Patients who underwent testing were more likely to be younger than 45 years (<italic toggle="yes">P</italic>&#160;&lt; .001), Black (<italic toggle="yes">P</italic>&#160;&lt; .001), Hispanic or Latino (<italic toggle="yes">P</italic>&#160;= .02); to not have Medicare insurance (<italic toggle="yes">P</italic>&#160;&lt; .001); and to have chronic rhinitis (<italic toggle="yes">P</italic>&#160;&lt; .001) (<xref rid="tbl1" ref-type="table">Table I</xref>). Patients who underwent testing were more likely to have received step-up therapy in the 90-day period after the index visit (<italic toggle="yes">P</italic>&#160;= .03).<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table I</label><caption><p>Patient characteristics related to aeroallergen testing among 1,412 adults with asthma</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Characteristic</th><th colspan="1" rowspan="1">Overall (n&#160;= 1,412)</th><th colspan="1" rowspan="1">No testing (n&#160;= 728)</th><th colspan="1" rowspan="1">Testing (n&#160;= 684)</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Age</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">&lt;.001</td></tr><tr><td colspan="1" rowspan="1">&#160;18-34 years</td><td align="char" colspan="1" rowspan="1">444 (31.4)</td><td align="char" colspan="1" rowspan="1">183 (25.1)</td><td align="char" colspan="1" rowspan="1">261 (38.2)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;35-44 years</td><td align="char" colspan="1" rowspan="1">257 (18.2)</td><td align="char" colspan="1" rowspan="1">114 (15.7)</td><td align="char" colspan="1" rowspan="1">143 (20.9)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;45-54 years</td><td align="char" colspan="1" rowspan="1">247 (17.5)</td><td align="char" colspan="1" rowspan="1">144 (19.8)</td><td align="char" colspan="1" rowspan="1">103 (15.1)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;55-64 years</td><td align="char" colspan="1" rowspan="1">226 (16.0)</td><td align="char" colspan="1" rowspan="1">135 (18.5)</td><td align="char" colspan="1" rowspan="1">91 (13.3)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;65+ years</td><td align="char" colspan="1" rowspan="1">238 (16.9)</td><td align="char" colspan="1" rowspan="1">152 (20.9)</td><td align="char" colspan="1" rowspan="1">86 (12.6)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Sex</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">.35</td></tr><tr><td colspan="1" rowspan="1">&#160;Male</td><td align="char" colspan="1" rowspan="1">308 (21.8)</td><td align="char" colspan="1" rowspan="1">166 (22.8)</td><td align="char" colspan="1" rowspan="1">142 (20.7)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Female</td><td align="char" colspan="1" rowspan="1">1,104 (78.2)</td><td align="char" colspan="1" rowspan="1">562 (77.2)</td><td align="char" colspan="1" rowspan="1">542 (79.2)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Race</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">&lt;.001</td></tr><tr><td colspan="1" rowspan="1">&#160;American Indian or Alaskan Native</td><td align="char" colspan="1" rowspan="1">8 (0.6)</td><td align="char" colspan="1" rowspan="1">0 (0.0)</td><td align="char" colspan="1" rowspan="1">8 (1.2)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Asian</td><td align="char" colspan="1" rowspan="1">65 (4.6)</td><td align="char" colspan="1" rowspan="1">33 (4.5)</td><td align="char" colspan="1" rowspan="1">32 (4.7)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Black</td><td align="char" colspan="1" rowspan="1">517 (36.6)</td><td align="char" colspan="1" rowspan="1">232 (31.9)</td><td align="char" colspan="1" rowspan="1">285 (41.7)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Native Hawaiian or other Pacific Islander</td><td align="char" colspan="1" rowspan="1">1 (0.1)</td><td align="char" colspan="1" rowspan="1">0 (0.0)</td><td align="char" colspan="1" rowspan="1">1 (0.1)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;White</td><td align="char" colspan="1" rowspan="1">821 (58.1)</td><td align="char" colspan="1" rowspan="1">463 (63.6)</td><td align="char" colspan="1" rowspan="1">358 (52.3)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Ethnicity</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">.02</td></tr><tr><td colspan="1" rowspan="1">&#160;Not Hispanic or Latino</td><td align="char" colspan="1" rowspan="1">1,377 (97.5)</td><td align="char" colspan="1" rowspan="1">717 (98.5)</td><td align="char" colspan="1" rowspan="1">660 (96.5)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Hispanic or Latino</td><td align="char" colspan="1" rowspan="1">35 (2.5)</td><td align="char" colspan="1" rowspan="1">11 (1.5)</td><td align="char" colspan="1" rowspan="1">24 (3.5)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Insurance</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">&lt;.001</td></tr><tr><td colspan="1" rowspan="1">&#160;Commercial</td><td align="char" colspan="1" rowspan="1">716 (50.7)</td><td align="char" colspan="1" rowspan="1">358 (49.2)</td><td align="char" colspan="1" rowspan="1">358 (52.3)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Medicaid</td><td align="char" colspan="1" rowspan="1">375 (26.6)</td><td align="char" colspan="1" rowspan="1">170 (23.4)</td><td align="char" colspan="1" rowspan="1">205 (30.0)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Medicare</td><td align="char" colspan="1" rowspan="1">321 (22.7)</td><td align="char" colspan="1" rowspan="1">200 (27.5)</td><td align="char" colspan="1" rowspan="1">121 (17.7)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">BMI</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">.84</td></tr><tr><td colspan="1" rowspan="1">&#160;Normal</td><td align="char" colspan="1" rowspan="1">407 (28.8)</td><td align="char" colspan="1" rowspan="1">220 (30.2)</td><td align="char" colspan="1" rowspan="1">187 (27.3)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Overweight</td><td align="char" colspan="1" rowspan="1">413 (29.2)</td><td align="char" colspan="1" rowspan="1">207 (28.4)</td><td align="char" colspan="1" rowspan="1">206 (30.1)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Class I obesity</td><td align="char" colspan="1" rowspan="1">265 (18.8)</td><td align="char" colspan="1" rowspan="1">136 (18.7)</td><td align="char" colspan="1" rowspan="1">129 (18.8)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Class II obesity</td><td align="char" colspan="1" rowspan="1">158 (11.2)</td><td align="char" colspan="1" rowspan="1">80 (11.0)</td><td align="char" colspan="1" rowspan="1">78 (11.4)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Class III obesity</td><td align="char" colspan="1" rowspan="1">169 (12.0)</td><td align="char" colspan="1" rowspan="1">85 (11.7)</td><td align="char" colspan="1" rowspan="1">84 (12.3)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Smoking category</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">.23</td></tr><tr><td colspan="1" rowspan="1">&#160;Never</td><td align="char" colspan="1" rowspan="1">965 (68.3)</td><td align="char" colspan="1" rowspan="1">483 (66.3)</td><td align="char" colspan="1" rowspan="1">482 (70.5)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Former</td><td align="char" colspan="1" rowspan="1">322 (22.8)</td><td align="char" colspan="1" rowspan="1">178 (24.5)</td><td align="char" colspan="1" rowspan="1">144 (21.0)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Current</td><td align="char" colspan="1" rowspan="1">125 (8.9)</td><td align="char" colspan="1" rowspan="1">67 (9.2)</td><td align="char" colspan="1" rowspan="1">58 (8.5)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">COPD</td><td align="char" colspan="1" rowspan="1">111 (7.9)</td><td align="char" colspan="1" rowspan="1">57 (7.8)</td><td align="char" colspan="1" rowspan="1">54 (7.9)</td><td align="char" colspan="1" rowspan="1">.96</td></tr><tr><td colspan="1" rowspan="1">Chronic rhinitis</td><td align="char" colspan="1" rowspan="1">1,328 (94.1)</td><td align="char" colspan="1" rowspan="1">652 (89.6)</td><td align="char" colspan="1" rowspan="1">676 (98.8)</td><td align="char" colspan="1" rowspan="1">&lt;.001</td></tr><tr><td colspan="1" rowspan="1">Inhaler category in the 12-month period before the index visit</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">.14</td></tr><tr><td colspan="1" rowspan="1">&#160;No ICS</td><td align="char" colspan="1" rowspan="1">724 (51.3)</td><td align="char" colspan="1" rowspan="1">352 (48.4)</td><td align="char" colspan="1" rowspan="1">372 (54.4)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;ICS only</td><td align="char" colspan="1" rowspan="1">195 (13.8)</td><td align="char" colspan="1" rowspan="1">110 (15.1)</td><td align="char" colspan="1" rowspan="1">85 (12.4)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;ICS/LABA</td><td align="char" colspan="1" rowspan="1">412 (29.2)</td><td align="char" colspan="1" rowspan="1">223 (30.6)</td><td align="char" colspan="1" rowspan="1">189 (27.6)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;ICS/LABA and LAMA</td><td align="char" colspan="1" rowspan="1">81 (5.7)</td><td align="char" colspan="1" rowspan="1">43 (5.9)</td><td align="char" colspan="1" rowspan="1">38 (5.6)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">OCS bursts in the 12-month period before the index visit</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">.70</td></tr><tr><td colspan="1" rowspan="1">&#160;0</td><td align="char" colspan="1" rowspan="1">930 (65.9)</td><td align="char" colspan="1" rowspan="1">484 (66.5)</td><td align="char" colspan="1" rowspan="1">446 (65.2)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;1</td><td align="char" colspan="1" rowspan="1">282 (20.0)</td><td align="char" colspan="1" rowspan="1">138 (19.0)</td><td align="char" colspan="1" rowspan="1">144 (21.1)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;2-3</td><td align="char" colspan="1" rowspan="1">149 (10.6)</td><td align="char" colspan="1" rowspan="1">77 (10.6)</td><td align="char" colspan="1" rowspan="1">72 (10.5)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;4 or more</td><td align="char" colspan="1" rowspan="1">51 (3.6)</td><td align="char" colspan="1" rowspan="1">29 (4.0)</td><td align="char" colspan="1" rowspan="1">22 (3.2)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Asthma ED visit in the 12-month period before the index visit</td><td align="char" colspan="1" rowspan="1">36 (2.5)</td><td align="char" colspan="1" rowspan="1">16 (2.2)</td><td align="char" colspan="1" rowspan="1">20 (2.9)</td><td align="char" colspan="1" rowspan="1">.39</td></tr><tr><td colspan="1" rowspan="1">Asthma hospitalization in the 12-month period before the index visit</td><td align="char" colspan="1" rowspan="1">21 (1.5)</td><td align="char" colspan="1" rowspan="1">10 (1.4)</td><td align="char" colspan="1" rowspan="1">11 (1.6)</td><td align="char" colspan="1" rowspan="1">.72</td></tr><tr><td colspan="1" rowspan="1">Step-up therapy after the index visit</td><td align="char" colspan="1" rowspan="1">491 (34.8)</td><td align="char" colspan="1" rowspan="1">234 (32.1)</td><td align="char" colspan="1" rowspan="1">257 (37.6)</td><td align="char" colspan="1" rowspan="1">.03</td></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as nos. (%). Patients who did not receive any testing (n&#160;= 728) were compared with patients who received any SPTs or serum-specific IgE tests on or within 90 days of index allergy/immunology visit (n&#160;= 684) by chi-square test.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2.2"><title>Documentation of likely reasons that providers did not perform testing, did perform testing, and performed serum-specific IgE testing</title><p id="p0090">The chart reviewers had 84% agreement in identifying the likely reasons that testing was not performed after initial review. After conferring on 8 (16%) of 50 charts that the reviewers disagreed on, consensus was achieved for all of them; the results are shown in <xref rid="tbl2" ref-type="table">Table II</xref>. Nineteen patients (38%) had prior test results in their charts, and most (n&#160;= 10) underwent testing 2 to 5 years before the index visit. Tests were ordered or planned but not completed for 10 patients (20%). Among 50 patients who underwent testing, the likely reason for testing was determined to be asthma and rhinitis for 26 patients (52%), whereas asthma alone was the likely reason for 5 patients (10%) (<xref rid="tbl3" ref-type="table">Table III</xref>). Among 50 patients who received serum-specific IgE tests, no likely reason for why it was performed could be identified for 24 patients (48%); the provider was unable to perform SPTs (eg, due to current antihistamine use) was the reason for 17 patients (34%); and the test-related encounter was a telemedicine visit was the reason for 9 patients (18%) (<xref rid="tbl4" ref-type="table">Table IV</xref>).<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table II</label><caption><p>Seven likely reasons why aeroallergen testing was not performed on or before the index visit</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Likely reason</th><th colspan="1" rowspan="1">No. (%)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><list list-type="simple" id="olist0010"><list-item id="o0010"><label>1.</label><p id="p0190">Prior test results available in chart</p></list-item></list></td><td align="char" colspan="1" rowspan="1">19 (38)</td></tr><tr><td colspan="1" rowspan="1">&#160;Testing between 2 and 5 years of the index visit</td><td align="char" colspan="1" rowspan="1">10 (20)</td></tr><tr><td colspan="1" rowspan="1">&#160;Testing &gt;5 years before the index visit</td><td align="char" colspan="1" rowspan="1">4 (8)</td></tr><tr><td colspan="1" rowspan="1">&#160;Year of testing not specified</td><td align="char" colspan="1" rowspan="1">4 (8)</td></tr><tr><td colspan="1" rowspan="1">&#160;Testing within 2 years of the index visit</td><td align="char" colspan="1" rowspan="1">2 (4)</td></tr><tr><td colspan="1" rowspan="1"><list list-type="simple" id="olist0015"><list-item id="o0015"><label>2.</label><p id="p0195">Test ordered or planned by Penn allergy/immunology provider but not completed</p></list-item></list></td><td align="char" colspan="1" rowspan="1">10 (20)</td></tr><tr><td colspan="1" rowspan="1"><list list-type="simple" id="olist0020"><list-item id="o0020"><label>3.</label><p id="p0200">Testing may not have been high priority for provider</p></list-item></list></td><td align="char" colspan="1" rowspan="1">9 (18)</td></tr><tr><td colspan="1" rowspan="1"><list list-type="simple" id="olist0025"><list-item id="o0025"><label>4.</label><p id="p0205">Patient self-report of previous testing</p></list-item></list></td><td align="char" colspan="1" rowspan="1">6 (12)</td></tr><tr><td colspan="1" rowspan="1"><list list-type="simple" id="olist0030"><list-item id="o0030"><label>5.</label><p id="p0210">Other or unspecified reason for testing not performed</p></list-item></list></td><td align="char" colspan="1" rowspan="1">4 (8)</td></tr><tr><td colspan="1" rowspan="1"><list list-type="simple" id="olist0035"><list-item id="o0035"><label>6.</label><p id="p0215">SPT contraindicated</p></list-item></list></td><td align="char" colspan="1" rowspan="1">1 (2)</td></tr><tr><td colspan="1" rowspan="1"><list list-type="simple" id="olist0040"><list-item id="o0040"><label>7.</label><p id="p0220">Patient declined testing for any reason</p></list-item></list></td><td align="char" colspan="1" rowspan="1">1 (2)</td></tr></tbody></table><table-wrap-foot><fn><p>Reasons are according to chart review of 50 patients who did not have codified aeroallergen testing according to structured EHR data. Reasons are ordered by decreasing percentage.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl3" orientation="portrait"><label>Table III</label><caption><p>Three likely reasons why aeroallergen testing was performed</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Likely reason</th><th colspan="1" rowspan="1">No. (%)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><list list-type="simple" id="olist0045"><list-item id="o0045"><label>1.</label><p id="p0225">Both rhinitis and asthma</p></list-item></list></td><td align="char" colspan="1" rowspan="1">26 (52)</td></tr><tr><td colspan="1" rowspan="1"><list list-type="simple" id="olist0050"><list-item id="o0050"><label>2.</label><p id="p0230">Rhinitis</p></list-item></list></td><td align="char" colspan="1" rowspan="1">19 (38)</td></tr><tr><td colspan="1" rowspan="1"><list list-type="simple" id="olist0055"><list-item id="o0055"><label>3.</label><p id="p0235">Asthma</p></list-item></list></td><td align="char" colspan="1" rowspan="1">5 (10)</td></tr></tbody></table><table-wrap-foot><fn><p>Reasons are according to chart review of 50 patients who had codified aeroallergen testing according to structured EHR data. Reasons are ordered by decreasing percentage.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl4" orientation="portrait"><label>Table IV</label><caption><p>Three likely reasons why serum-specific IgE tests were provided instead of SPTs</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Reason</th><th colspan="1" rowspan="1">No. (%)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><list list-type="simple" id="olist0060"><list-item id="o0060"><label>1.</label><p id="p0240">No reason identified</p></list-item></list></td><td align="char" colspan="1" rowspan="1">24 (48)</td></tr><tr><td colspan="1" rowspan="1"><list list-type="simple" id="olist0065"><list-item id="o0065"><label>2.</label><p id="p0245">Provider was unable to perform skin testing<xref rid="tbl4fnlowast" ref-type="table-fn">&#8727;</xref></p></list-item></list></td><td align="char" colspan="1" rowspan="1">17 (34)</td></tr><tr><td colspan="1" rowspan="1"><list list-type="simple" id="olist0070"><list-item id="o0070"><label>3.</label><p id="p0250">Testing-related encounter was a telemedicine visit</p></list-item></list></td><td align="char" colspan="1" rowspan="1">9 (18)</td></tr></tbody></table><table-wrap-foot><fn><p>Reasons are according to chart review of 50 patients with serum-specific IgE test. Two reasons were identified for approximately half of patients, while no clear reason was identified for the remainder.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl4fnlowast"><label>&#8727;</label><p id="ntpara0010">For example, because of current antihistamine receipt.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2.3"><title>Testing was not associated with fewer OCS bursts after the index visit among all patients</title><p id="p0095">According to the primary analysis of 1,412 patients, testing was not associated with fewer OCS bursts (incidence rate ratio [IRR]&#160;= 0.84 vs no testing, <italic toggle="yes">P</italic>&#160;= .08) (<xref rid="tbl5" ref-type="table">Table V</xref>). The IRRs for all independent variables are shown in <xref rid="appsec1" ref-type="sec">Table E4</xref> in the Online Repository available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.jaci-global.org" id="intref0020">www.jaci-global.org</ext-link>. The variance inflation factors were less than 1.7, indicating minimal collinearity (see <xref rid="appsec1" ref-type="sec">Table E5</xref> in the Online Repository).<table-wrap position="float" id="tbl5" orientation="portrait"><label>Table V</label><caption><p>Effect of aeroallergen testing on OCS burst count in 12-month period after the index allergy/immunology visit</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Characteristic</th><th colspan="1" rowspan="1">Variable</th><th colspan="1" rowspan="1">Value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Overall cohort (N&#160;= 1,412)</td><td colspan="1" rowspan="1">IRR (95% CI)</td><td align="char" colspan="1" rowspan="1">0.84 (0.70, 1.02)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</td><td colspan="1" rowspan="1">.08</td></tr><tr><td colspan="1" rowspan="1">Index visit before COVID-19 lockdown (n&#160;= 997)</td><td colspan="1" rowspan="1">IRR (95% CI)</td><td align="char" colspan="1" rowspan="1">0.78 (0.62, 0.98)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</td><td colspan="1" rowspan="1">.04</td></tr><tr><td colspan="1" rowspan="1">Overall cohort, no COPD (n&#160;= 1,301)</td><td colspan="1" rowspan="1">IRR (95% CI)</td><td align="char" colspan="1" rowspan="1">0.85 (0.69, 1.05)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</td><td colspan="1" rowspan="1">.13</td></tr><tr><td colspan="1" rowspan="1">Overall cohort, no COPD and never smokers (n&#160;= 927)</td><td colspan="1" rowspan="1">IRR (95% CI)</td><td align="char" colspan="1" rowspan="1">0.69 (0.54, 0.90)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</td><td colspan="1" rowspan="1">.005</td></tr></tbody></table><table-wrap-foot><fn><p>IRRs were adjusted for all independent variables (age, sex, race, ethnicity, insurance status, BMI, smoking category, COPD, chronic rhinitis, inhaler category, OCS bursts, asthma ED visits, and asthma hospitalizations in 12-month period before the index visit) in multivariable models using data from full cohort of 1,412 adults with asthma who established outpatient allergy/immunology care. This model was repeated for subgroups of 1,412 patients: 997 whose index visits and postvisit 90-day periods occurred before COVID-19 lockdown (same covariates as overall cohort); 1,176 who did not have COPD (COPD was not included as covariate); and 860 who did not have COPD and were never smokers (COPD and smoking category were not included as covariates).</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2.4"><title>Influence of COVID-19 pandemic</title><p id="p0100"><xref rid="fig2" ref-type="fig">Fig 2</xref> shows the rates of testing via SPTs and serum-specific IgE tests over time. From January 2017 to April 2020, testing via SPTs was performed at a higher rate except for October-December 2019. After the COVID-19 lockdown date, the rate of testing via SPTs declined while the rate via serum-specific IgE tests increased. Thereafter, the rate of testing via SPTs increased. A&#160;total of 997 (70.6%) of 1,412 index visits and 90-day postvisit periods occurred before the lockdown date, and for these patients, testing was associated with fewer bursts in the multivariable analysis (IRR&#160;= 0.78, <italic toggle="yes">P</italic>&#160;= .04) (<xref rid="tbl5" ref-type="table">Table V</xref>).<fig id="fig2" position="float" orientation="portrait"><label>Fig 2</label><caption><p>Three-month rates of testing via SPTs and serum-specific IgE tests for 668 patients who had an index visit between January 1, 2017, and June 30, 2022, and underwent testing at the visit or up to 90 days after. Rates of testing represent ratios of the number of patients tested to the number of index visits within each 3-month period. The <italic toggle="yes">Black dotted line</italic> represents 3-month period during which COVID-19 lockdown in Philadelphia occurred.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p></sec><sec id="sec2.5"><title>Testing was associated with fewer OCS bursts among patients who did not have COPD and were never smokers</title><p id="p0105">Among 1,301 (92.1%) of 1,412 patients without COPD, 630 (48.4%) underwent testing, and testing was not associated with fewer OCS bursts (IRR&#160;= 0.85, <italic toggle="yes">P</italic>&#160;= .13) (<xref rid="tbl5" ref-type="table">Table V</xref>). Among 927 (65.7%) of 1,412 never smokers without COPD, 461 (49.7%) underwent testing, and testing was associated with fewer bursts (IRR&#160;= 0.69, <italic toggle="yes">P</italic>&#160;= .005) (<xref rid="tbl5" ref-type="table">Table V</xref>).</p></sec><sec id="sec2.6"><title>Sensitization to 5-7 aeroallergen categories was associated with fewer OCS bursts after the index visit among patients who did not have COPD and were never smokers</title><p id="p0110">Among 1,255 patients who either did not undergo testing or who underwent testing to 7 aeroallergen categories and had sensitization to at least one, 292 (23.3%) had sensitization to 1-4 categories and 235 (18.7%) to 5-7 categories. Compared with patients who did not undergo testing, there were no associations of sensitization to 1-4 categories (IRR&#160;= 0.85, <italic toggle="yes">P</italic>&#160;= .21) or 5-7 categories (IRR&#160;= 0.79, <italic toggle="yes">P</italic>&#160;= .11) with fewer OCS bursts. Results of the primary and 3 secondary analyses are shown in <xref rid="tbl6" ref-type="table">Table VI</xref>. Among 830 never smokers without COPD, sensitization to 5-7 categories was associated with fewer bursts (IRR&#160;= 0.57, <italic toggle="yes">P</italic>&#160;= .003), whereas sensitization to 1-4 categories was not (IRR&#160;= 0.83, <italic toggle="yes">P</italic>&#160;= .25).<table-wrap position="float" id="tbl6" orientation="portrait"><label>Table VI</label><caption><p>Effect of aeroallergen testing on OCS burst count in 12-month period after the index allergy/immunology visit while considering sensitization to 1-4 or 5-7 aeroallergen categories among categories of tree, grass, weed, dust mite, cat, dog, and mold</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Characteristic</th><th colspan="1" rowspan="1">Variable</th><th colspan="1" rowspan="1">Value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Overall cohort (N&#160;= 1,255)</td><td colspan="1" rowspan="1">Sensitization to 1-4 categories</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;IRR (95% CI)</td><td align="char" colspan="1" rowspan="1">0.85 (0.67, 1.09)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;<italic toggle="yes">P</italic> value</td><td colspan="1" rowspan="1">.21</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Sensitization to 5-7 categories</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;IRR (95% CI)</td><td align="char" colspan="1" rowspan="1">0.79 (0.59, 1.05)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;<italic toggle="yes">P</italic> value</td><td colspan="1" rowspan="1">.11</td></tr><tr><td colspan="1" rowspan="1">Index visit before COVID-19 lockdown (n&#160;= 887)</td><td colspan="1" rowspan="1">Sensitization to 1-4 categories</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;IRR (95% CI)</td><td align="char" colspan="1" rowspan="1">0.83 (0.62, 1.13)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;<italic toggle="yes">P</italic> value</td><td colspan="1" rowspan="1">.24</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Sensitization to 5-7 categories</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;IRR (95% CI)</td><td align="char" colspan="1" rowspan="1">0.76 (0.54, 1.06)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;<italic toggle="yes">P</italic> value</td><td colspan="1" rowspan="1">.11</td></tr><tr><td colspan="1" rowspan="1">Overall cohort, no COPD (n&#160;= 1,162)</td><td colspan="1" rowspan="1">Sensitization to 1-4 categories</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;IRR (95% CI)</td><td align="char" colspan="1" rowspan="1">0.89 (0.68, 1.16)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;<italic toggle="yes">P</italic> value</td><td colspan="1" rowspan="1">.37</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Sensitization to 5-7 categories</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;IRR (95% CI)</td><td align="char" colspan="1" rowspan="1">0.79 (0.58, 1.08)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;<italic toggle="yes">P</italic> value</td><td colspan="1" rowspan="1">.14</td></tr><tr><td colspan="1" rowspan="1">Overall cohort, no COPD and never smokers (n&#160;= 830)</td><td colspan="1" rowspan="1">Sensitization to 1-4 categories</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;IRR (95% CI)</td><td align="char" colspan="1" rowspan="1">0.83 (0.61, 1.14)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;<italic toggle="yes">P</italic> value</td><td colspan="1" rowspan="1">.25</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Sensitization to 5-7 categories</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;IRR (95% CI)</td><td align="char" colspan="1" rowspan="1">0.57 (0.39, 0.82)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;<italic toggle="yes">P</italic> value</td><td colspan="1" rowspan="1">.003</td></tr></tbody></table><table-wrap-foot><fn><p>IRRs were adjusted for all independent variables (age, sex, race, ethnicity, insurance status, BMI, smoking category, COPD, chronic rhinitis, inhaler category, OCS bursts, asthma ED visits, and asthma hospitalizations in the 12-month period before the index visit) in multivariable models using data from 1,255 patients among 1,412 in overall cohort who either did not undergo testing or who underwent testing to 7 aeroallergen categories and had sensitization to at least one. This model was repeated for subgroups of 1,255 patients: 887 whose index visits and postvisit 90-day periods occurred before the COVID-19 lockdown (same covariates as overall cohort); 1,162 who did not have COPD (COPD was not included as a covariate); and 830 who did not have COPD and were never smokers (COPD and smoking category were not included as covariates).</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2.7"><title>Receipt of SPTs was associated with fewer OCS bursts after the index visit</title><p id="p0115">Among 684 patients who underwent testing, 430 (62.9%) received SPTs and 254 (37.1%) received only serum-specific IgE tests. Comparing these 2 subgroups, patients who received SPTs were more likely to be under age 45 (<italic toggle="yes">P</italic>&#160;&lt; .001), to have commercial insurance (<italic toggle="yes">P</italic>&#160;&lt; .001), to have normal or overweight BMI (<italic toggle="yes">P</italic>&#160;&lt; .001), to not have COPD (<italic toggle="yes">P</italic>&#160;= .001), and to not be receiving ICS (<italic toggle="yes">P</italic>&#160;= .006) or to have received OCS bursts (<italic toggle="yes">P</italic>&#160;= .02) in the year before the index visit (see <xref rid="appsec1" ref-type="sec">Table E3</xref> in the Online Repository available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.jaci-global.org" id="intref0025">www.jaci-global.org</ext-link>). According to the multivariable analyses that used the 3-level test modality variable, the receipt of SPTs was associated with fewer bursts (IRR&#160;&#8804; 0.78 vs no testing, <italic toggle="yes">P</italic>&#160;&#8804; .03 for SPTs vs no testing in each of the primary and secondary analyses), whereas the receipt of only serum-specific IgE tests&#160;was not (<italic toggle="yes">P</italic>&#160;&gt; .05 in the primary and secondary analyses) (<xref rid="tbl7" ref-type="table">Table VII</xref>).<table-wrap position="float" id="tbl7" orientation="portrait"><label>Table VII</label><caption><p>Effect of the receipt of SPTs and serum-specific IgE tests on OCS burst count in 12-month period after the index allergy/immunology visit</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Characteristic</th><th colspan="1" rowspan="1">Variable</th><th colspan="1" rowspan="1">Value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Overall cohort (N&#160;= 1,412)</td><td colspan="1" rowspan="1">SPTs</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;IRR (95% CI)</td><td align="char" colspan="1" rowspan="1">0.78 (0.62, 0.98)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;<italic toggle="yes">P</italic> value</td><td colspan="1" rowspan="1">.03</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Only serum-specific IgE tests</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;IRR (95% CI)</td><td align="char" colspan="1" rowspan="1">0.93 (0.72, 1.19)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;<italic toggle="yes">P</italic> value</td><td colspan="1" rowspan="1">.55</td></tr><tr><td colspan="1" rowspan="1">Index visit before COVID-19 lockdown (n&#160;= 997)</td><td colspan="1" rowspan="1">SPTs</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;IRR (95% CI)</td><td align="char" colspan="1" rowspan="1">0.74 (0.57, 0.96)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;<italic toggle="yes">P</italic> value</td><td colspan="1" rowspan="1">.02</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Only serum-specific IgE tests</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;IRR (95% CI)</td><td align="char" colspan="1" rowspan="1">0.86 (0.63, 1.18)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;<italic toggle="yes">P</italic> value</td><td colspan="1" rowspan="1">.36</td></tr><tr><td colspan="1" rowspan="1">Overall cohort, no COPD (n&#160;= 1,301)</td><td colspan="1" rowspan="1">SPTs</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;IRR (95% CI)</td><td align="char" colspan="1" rowspan="1">0.76 (0.60, 0.97)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;<italic toggle="yes">P</italic> value</td><td colspan="1" rowspan="1">.03</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Only serum-specific IgE tests</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;IRR (95% CI)</td><td align="char" colspan="1" rowspan="1">0.99 (0.76, 1.30)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;<italic toggle="yes">P</italic> value</td><td colspan="1" rowspan="1">.96</td></tr><tr><td colspan="1" rowspan="1">Overall cohort, no COPD and never smokers (n&#160;= 927)</td><td colspan="1" rowspan="1">SPTs</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;IRR (95% CI)</td><td align="char" colspan="1" rowspan="1">0.58 (0.43, 0.78)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;<italic toggle="yes">P</italic> value</td><td colspan="1" rowspan="1">&lt;.0005</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">Only serum-specific IgE tests</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;IRR (95% CI)</td><td align="char" colspan="1" rowspan="1">0.90 (0.65, 1.25)</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#160;<italic toggle="yes">P</italic> value</td><td colspan="1" rowspan="1">.54</td></tr></tbody></table><table-wrap-foot><fn><p>IRRs were adjusted for all independent variables (age, sex, race, ethnicity, insurance status, BMI, smoking category, COPD, chronic rhinitis, inhaler category, OCS bursts, asthma ED visits, and asthma hospitalizations in 12-month period before the index visit) in multivariable models using data from full cohort of 1,412 adults with asthma who established outpatient allergy/immunology care. This model was repeated for subgroups of 1,412 patients: 997 whose index visits and postvisit 90-day periods occurred before COVID-19 lockdown (same covariates as overall cohort); 1,301 who did not have COPD (COPD was not included as a covariate); and 927 who did not have COPD and were never smokers (COPD and smoking category were not included as covariates).</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec id="sec3"><title>Discussion</title><p id="p0120">In this study of adults with asthma in a large health system who established care in an allergy/immunology clinic and for whom aeroallergen testing appeared to be indicated according to the guidelines, aeroallergen testing was associated with fewer OCS bursts in the 12-month period after the index visit among never smokers without COPD. Within this subgroup, sensitization to 5-7 aeroallergen categories, but not 1-4 categories, was associated with fewer bursts. These findings did not extend to all asthma patients. We also found that testing via SPTs but not serum-specific IgE tests was associated with fewer bursts for the full cohort and in each secondary analysis.</p><p id="p0125">Thirty-eight percent of patients categorized as not having undergone testing had prior test results available in the EHR. While these patients&#8217; testing status may be considered misclassified, an alternative view is that some previously tested patients could benefit from repeat testing. Notably, 20% of patients who underwent chart review had tests ordered or planned but not performed. Insofar as these patients were nonadherent to providers&#8217; recommendations, it is possible that they were less adherent overall (eg, to inhaler therapy) than patients who underwent testing after the index visit. Therefore, differences in adherence between the tested and untested patients, irrespective of the testing itself, may have contributed to differences in OCS bursts after the index visit. Among patients who underwent testing, only 10% had asthma alone&#8212;and not rhinitis or both asthma and rhinitis&#8212;listed as the likely reason for testing. Most patients with asthma have rhinitis,<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib29" ref-type="bibr"><sup>28</sup></xref> which may explain why most patients had both asthma and rhinitis listed as the reason for ordering tests. More research is needed to understand why tests are performed in patients with asthma with and without rhinitis.</p><p id="p0130">Our findings suggest that testing in accordance with the guidelines offers clinical benefit among asthma patients who do not have COPD or a history of smoking. It is possible that patient-driven behavioral changes or greater awareness of asthma triggers were mediators between testing and fewer OCS bursts; this is supported by our finding that among never smokers without COPD, sensitization to 5-7 aeroallergen categories was associated with fewer OCS bursts, whereas sensitization to 1-4 categories was not. Interestingly, we found that patients who underwent testing were more likely to receive step-up therapy after the index visit, offering another possible explanation for fewer bursts. According to expert consensus in the Global Initiative for Asthma guidelines, allergen exposure, if sensitized, is a rationale for step-up treatment.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> However, we were unable to measure whether the test results prompted step-up therapy. It is also possible that the need for step-up therapy motivated providers to order tests or that both step-up therapy and testing comprised a comprehensive care strategy. More research is needed to evaluate whether aeroallergen testing is independently associated with clinical benefit and whether step-up inhaler therapy mediates this association.</p><p id="p0135">We observed that before the COVID-19 lockdown in Philadelphia, SPTs were performed at a higher rate than serum-specific IgE tests, but these rates became more similar after March 2020, presumably due to the rise in telemedicine encounters. This is supported by the finding in the chart review that 18% of patients likely received serum-specific IgE tests because the test-related visit was a telemedicine encounter. Prior research has found numerous changes in asthma-related health care utilization during the pandemic, including an increase in telemedicine and reductions in asthma exacerbations.<xref rid="bib30" ref-type="bibr">29</xref>, <xref rid="bib31" ref-type="bibr">30</xref>, <xref rid="bib32" ref-type="bibr">31</xref>, <xref rid="bib33" ref-type="bibr">32</xref>, <xref rid="bib34" ref-type="bibr">33</xref>, <xref rid="bib35" ref-type="bibr">34</xref>, <xref rid="bib36" ref-type="bibr">35</xref>, <xref rid="bib37" ref-type="bibr">36</xref>, <xref rid="bib38" ref-type="bibr">37</xref>, <xref rid="bib39" ref-type="bibr">38</xref> We performed a secondary analysis restricting the index visit dates to those that occurred before the lockdown and observed greater benefit from testing than in the overall cohort. This may reflect a differential benefit according to test type: patients whose index visits occurred before the lockdown received SPTs at a higher rate.</p><p id="p0140">Asthma associated with comorbid COPD or smoking represents difficult-to-treat subtypes with distinct patterns of airway inflammation and airway remodeling.<xref rid="bib40" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="bib41" ref-type="bibr"><sup>40</sup></xref> Our results may reflect less effectiveness of testing among patients with asthma and smoking-related comorbidity. Alternatively, because patients with COPD or smoking histories were older, and because older adults with asthma are less likely to be sensitized to aeroallergens,<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="bib21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="bib42" ref-type="bibr"><sup>41</sup></xref> older age may underlie their relative lack of benefit from testing. Prospective studies are needed to clarify these relationships.</p><p id="p0145">Testing via SPTs may be more beneficial than via serum-specific IgE tests because the former offers immediate results that can be incorporated into management plans at the same visit. However, a caveat of comparing the 2 test modalities is that compared with patients who received SPTs, patients who received only serum-specific IgE tests were more likely to have COPD, be prescribed more controller inhalers, and have had more OCS bursts before the index visit. The reasons for these patient differences in test selection are unknown, although for patients with more severe or uncontrolled asthma, providers may deprioritize a 20-minute skin test procedure in favor of other tests at the visit (eg, spirometry), or they may choose to bundle serum-specific IgE tests with other serologic tests. It is possible that residual confounding related to patient selection accounted for the observed differences in OCS bursts after the index visit according to test type. Specifically, we were unable to account for asthma control, environmental exposures, and genetic risk factors for asthma exacerbations.</p><p id="p0150">This study has several additional limitations. Persistent asthma is a clinical diagnosis, but we used ICS prescriptions to classify asthma as persistent, which may misclassify asthma that has been over- or undertreated. However, because misclassification usually biases toward the null, our results suggest a benefit of aeroallergen testing among patients in the cohort whose disease was correctly classified as persistent asthma and thus should have, according to the guidelines, undergone testing. Although airflow obstruction is a risk factor for asthma exacerbations<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> and aeroallergen testing with allergen avoidance education has been found to improve lung function,<xref rid="bib25" ref-type="bibr"><sup>24</sup></xref> we were unable to incorporate pulmonary function testing results due to inadequate data capture (eg, testing not documented as being performed or lung volumes not accompanied by flow volume curves). Our results may not be generalizable to other health systems. However, our findings within a diverse, predominantly urban cohort of adults with asthma may generalize to similar health systems. It is possible that patients who underwent aeroallergen testing were more likely to have received asthma-related education, and this education may have improved outcomes regardless of the testing. Finally, we were unable to count OCS prescriptions issued by providers outside Penn.</p><p id="p0155">In summary, we found that in our diverse health system where asthma morbidity is high and asthma disparities exist, patients with asthma who were never smokers without COPD who underwent aeroallergen testing in the context of an outpatient allergy/immunology visit had fewer OCS bursts in the 12-month period after testing. In addition, among all patients with asthma, the receipt of SPTs was associated with fewer OCS bursts in the 12-month period after testing.<boxed-text id="dtbox1" position="float" orientation="portrait"><caption><title>Clinical implication</title></caption><p id="p0160">Among adults with asthma, aeroallergen testing may improve asthma outcomes for never smokers without COPD and for patients who receive SPTs.</p></boxed-text></p></sec><sec sec-type="COI-statement"><title>Disclosure statement</title><p id="p0170">Research reported in this publication was supported by the <funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source> (NIH) National Heart, Lung, and Blood Institute under awards R01HL162354 and K24HL115354; and the <funding-source id="gs6"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000066</institution-id><institution>National Institute of Environmental Health Sciences</institution></institution-wrap></funding-source> under awards T32ES019851 and P30ES013508. Additional funding was provided by the Pennsylvania Allergy Education Research Fund and the <funding-source id="gs7"><institution-wrap><institution-id institution-id-type="doi">10.13039/100006093</institution-id><institution>Patient-Centered Outcomes Research Institute</institution></institution-wrap></funding-source> 25 under award AS-1307-05218. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the report. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or other funding agencies.</p><p id="p0175">Disclosure of potential conflict of interest: K. H. Morales owns stock in Altria Group, British American Tobacco, and Phillip Morris International. The rest of the authors declare that they have no relevant conflicts of interest.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="other" id="sref1"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention</collab></person-group><article-title>Uncontrolled asthma among adults</article-title><comment>Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/asthma/asthma_stats/uncontrolled-asthma-adults-2019.htm" id="intref0030">https://www.cdc.gov/asthma/asthma_stats/uncontrolled-asthma-adults-2019.htm</ext-link></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="other" id="sref2"><person-group person-group-type="author"><collab>Global Initiative for Asthma (GINA)</collab></person-group><article-title>Global strategy for asthma management and prevention (2023 update)</article-title><comment>Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ginasthma.org/archived-reports/" id="intref0035">https://ginasthma.org/archived-reports/</ext-link></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Nurmagambetov</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kuwahara</surname><given-names>R.</given-names></name><name name-style="western"><surname>Garbe</surname><given-names>P.</given-names></name></person-group><article-title>The economic burden of asthma in the United States, 2008-2013</article-title><source>Ann Am Thorac Soc</source><volume>15</volume><year>2018</year><fpage>348</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">29323930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1513/AnnalsATS.201703-259OC</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><collab>National Asthma Education and Prevention Program</collab></person-group><article-title>Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma&#8212;summary report, 2007</article-title><source>J Allergy Clin Immunol</source><volume>120</volume><issue>5 suppl</issue><year>2007</year><fpage>S94</fpage><lpage>S138</lpage><pub-id pub-id-type="pmid">17983880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaci.2007.09.043</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Olivieri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heinrich</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schl&#252;nssen</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ant&#243;</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Forsberg</surname><given-names>B.</given-names></name><name name-style="western"><surname>Janson</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The risk of respiratory symptoms on allergen exposure increases with increasing specific IgE levels</article-title><source>Allergy</source><volume>71</volume><year>2016</year><fpage>859</fpage><lpage>868</lpage><pub-id pub-id-type="pmid">26764559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/all.12841</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Douglass</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Lodge</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Thunderstorm asthma in seasonal allergic rhinitis: the TAISAR study</article-title><source>J Allergy Clin Immunol</source><volume>149</volume><year>2022</year><fpage>1607</fpage><lpage>1616</lpage><pub-id pub-id-type="pmid">34774618</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaci.2021.10.028</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Grant</surname><given-names>T.</given-names></name><name name-style="western"><surname>Aloe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Perzanowski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Phipatanakul</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bollinger</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Mouse sensitization and exposure are associated with asthma severity in urban children</article-title><source>J Allergy Clin Immunol Pract</source><volume>5</volume><year>2017</year><fpage>1008</fpage><lpage>1014.e1</lpage><pub-id pub-id-type="pmid">27923647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaip.2016.10.020</pub-id><pub-id pub-id-type="pmcid">PMC5457718</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Rosenstreich</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Eggleston</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kattan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>D.</given-names></name><name name-style="western"><surname>Slavin</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Gergen</surname><given-names>P.</given-names></name><etal/></person-group><article-title>The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma</article-title><source>N Engl J Med</source><volume>336</volume><year>1997</year><fpage>1356</fpage><lpage>1363</lpage><pub-id pub-id-type="pmid">9134876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM199705083361904</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Rabito</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>He</surname><given-names>H.</given-names></name><name name-style="western"><surname>Werthmann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schal</surname><given-names>C.</given-names></name></person-group><article-title>A single intervention for cockroach control reduces cockroach exposure and asthma morbidity in children</article-title><source>J Allergy Clin Immunol</source><volume>140</volume><year>2017</year><fpage>565</fpage><lpage>570</lpage><pub-id pub-id-type="pmid">28108117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaci.2016.10.019</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Mistry</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ajsivinac Soberanis</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Kyyaly</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Azim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barber</surname><given-names>C.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>D.</given-names></name><etal/></person-group><article-title>The clinical implications of <italic toggle="yes">Aspergillus fumigatus</italic> sensitization in difficult-to-treat asthma patients</article-title><source>J Allergy Clin Immunol Pract</source><volume>9</volume><year>2021</year><fpage>4254</fpage><lpage>4267.e10</lpage><pub-id pub-id-type="pmid">34534722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaip.2021.08.038</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Pulimood</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Corden</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Bryden</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sharples</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nasser</surname><given-names>S.M.</given-names></name></person-group><article-title>Epidemic asthma and the role of the fungal mold <italic toggle="yes">Alternaria alternata</italic></article-title><source>J Allergy Clin Immunol</source><volume>120</volume><year>2007</year><fpage>610</fpage><lpage>617</lpage><pub-id pub-id-type="pmid">17624415</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaci.2007.04.045</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Arroyave</surname><given-names>W.D.</given-names></name><name name-style="western"><surname>Rabito</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>J.C.</given-names></name></person-group><article-title>The relationship between a specific IgE level and asthma outcomes: results from the 2005-2006 National Health and Nutrition Examination Survey</article-title><source>J Allergy Clin Immunol Pract</source><volume>1</volume><year>2013</year><fpage>501</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">24565622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaip.2013.06.013</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Osborne</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Pedula</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>O&#8217;Hollaren</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ettinger</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Stibolt</surname><given-names>T.</given-names></name><name name-style="western"><surname>Buist</surname><given-names>A.S.</given-names></name><etal/></person-group><article-title>Assessing future need for acute care in adult asthmatics: the Profile of Asthma Risk Study: a prospective health maintenance organization-based study</article-title><source>Chest</source><volume>132</volume><year>2007</year><fpage>1151</fpage><lpage>1161</lpage><pub-id pub-id-type="pmid">17573515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1378/chest.05-3084</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Gergen</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Calatroni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sever</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Cohn</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Salo</surname><given-names>P.M.</given-names></name><etal/></person-group><article-title>Sensitization and exposure to pets: the effect on asthma morbidity in the US population</article-title><source>J Allergy Clin Immunol Pract</source><volume>6</volume><year>2018</year><fpage>101</fpage><lpage>107.e2</lpage><pub-id pub-id-type="pmid">28694047</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaip.2017.05.019</pub-id><pub-id pub-id-type="pmcid">PMC5756688</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Goh</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Yii</surname><given-names>A.C.A.</given-names></name><name name-style="western"><surname>Lapperre</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Chew</surname><given-names>F.T.</given-names></name><name name-style="western"><surname>Chotirmall</surname><given-names>S.H.</given-names></name><etal/></person-group><article-title>Sensitization to <italic toggle="yes">Aspergillus</italic> species is associated with frequent exacerbations in severe asthma</article-title><source>J Asthma Allergy</source><volume>10</volume><year>2017</year><fpage>131</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">28461762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JAA.S130459</pub-id><pub-id pub-id-type="pmcid">PMC5407445</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Driscoll</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Hopkinson</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Denning</surname><given-names>D.W.</given-names></name></person-group><article-title>Mold sensitization is common amongst patients with severe asthma requiring multiple hospital admissions</article-title><source>BMC Pulm Med</source><volume>5</volume><year>2005</year><fpage>4</fpage><pub-id pub-id-type="pmid">15720706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2466-5-4</pub-id><pub-id pub-id-type="pmcid">PMC550663</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Medrek</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Kao</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Hanania</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Parulekar</surname><given-names>A.D.</given-names></name></person-group><article-title>Fungal sensitization is associated with increased risk of life-threatening asthma</article-title><source>J Allergy Clin Immunol Pract</source><volume>5</volume><year>2017</year><fpage>1025</fpage><lpage>1031.e2</lpage><pub-id pub-id-type="pmid">28017627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaip.2016.11.015</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Fairs</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agbetile</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hargadon</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bourne</surname><given-names>M.</given-names></name><name name-style="western"><surname>Monteiro</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Brightling</surname><given-names>C.E.</given-names></name><etal/></person-group><article-title>IgE sensitization to <italic toggle="yes">Aspergillus fumigatus</italic> is associated with reduced lung function in asthma</article-title><source>Am J Respir Crit Care Med</source><volume>182</volume><year>2010</year><fpage>1362</fpage><lpage>1368</lpage><pub-id pub-id-type="pmid">20639442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201001-0087OC</pub-id><pub-id pub-id-type="pmcid">PMC3029929</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Salo</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Arbes</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Crockett</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Thorne</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Cohn</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Zeldin</surname><given-names>D.C.</given-names></name></person-group><article-title>Exposure to multiple indoor allergens in US homes and its relationship to asthma</article-title><source>J Allergy Clin Immunol</source><volume>121</volume><year>2008</year><fpage>678</fpage><lpage>684.e2</lpage><pub-id pub-id-type="pmid">18255132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaci.2007.12.1164</pub-id><pub-id pub-id-type="pmcid">PMC2376121</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Gleeson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Morales</surname><given-names>K.</given-names></name><name name-style="western"><surname>Buckey</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fadugba</surname><given-names>O.</given-names></name><name name-style="western"><surname>Apter</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Himes</surname><given-names>B.</given-names></name></person-group><article-title>Factors associated with aeroallergen testing among adults with asthma in a large health system</article-title><source>J Allergy Clin Immunol Glob</source><volume>2</volume><year>2023</year><object-id pub-id-type="publisher-id">100167</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacig.2023.100167</pub-id><pub-id pub-id-type="pmcid">PMC10570953</pub-id><pub-id pub-id-type="pmid">37841071</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Teague</surname><given-names>W.G.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Fahy</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Wenzel</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>W.C.</given-names></name><etal/></person-group><article-title>Baseline Features of the Severe Asthma Research Program (SARP III) cohort: differences with age</article-title><source>J Allergy Clin Immunol Pract</source><volume>6</volume><year>2018</year><fpage>545</fpage><lpage>554.e4</lpage><pub-id pub-id-type="pmid">28866107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaip.2017.05.032</pub-id><pub-id pub-id-type="pmcid">PMC5832534</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Fowler</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Fleming</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>G.</given-names></name><name name-style="western"><surname>Corfield</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort</article-title><source>Eur Respir J</source><volume>46</volume><year>2015</year><fpage>1308</fpage><lpage>1321</lpage><pub-id pub-id-type="pmid">26357963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.00779-2015</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Salo</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Wilkerson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Cohn</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Calatroni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>H.E.</given-names></name><etal/></person-group><article-title>Bedroom allergen exposures in US households</article-title><source>J Allergy Clin Immunol</source><volume>141</volume><year>2018</year><fpage>1870</fpage><lpage>1879.e14</lpage><pub-id pub-id-type="pmid">29198587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaci.2017.08.033</pub-id><pub-id pub-id-type="pmcid">PMC5938098</pub-id></element-citation></ref><ref id="bib25"><label>24</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Bobb</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ritz</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rowlands</surname><given-names>G.</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>C.</given-names></name></person-group><article-title>Effects of allergen and trigger factor avoidance advice in primary care on asthma control: a randomized-controlled trial</article-title><source>Clin Exp Allergy</source><volume>40</volume><year>2010</year><fpage>143</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">19793085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2222.2009.03350.x</pub-id></element-citation></ref><ref id="bib26"><label>25</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Janson</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>McGrath</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Covington</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Boushey</surname><given-names>H.A.</given-names></name></person-group><article-title>Individualized asthma self-management improves medication adherence and markers of asthma control</article-title><source>J Allergy Clin Immunol</source><volume>123</volume><year>2009</year><fpage>840</fpage><lpage>846</lpage><pub-id pub-id-type="pmid">19348923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaci.2009.01.053</pub-id><pub-id pub-id-type="pmcid">PMC2729175</pub-id></element-citation></ref><ref id="bib27"><label>26</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><collab>Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC)</collab><name name-style="western"><surname>Cloutier</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Baptist</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Blake</surname><given-names>K.V.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Bryant-Stephens</surname><given-names>T.</given-names></name><etal/></person-group><article-title>2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group</article-title><source>J Allergy Clin Immunol</source><volume>146</volume><year>2020</year><fpage>1217</fpage><lpage>1270</lpage><pub-id pub-id-type="pmid">33280709</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaci.2020.10.003</pub-id><pub-id pub-id-type="pmcid">PMC7924476</pub-id></element-citation></ref><ref id="bib28"><label>27</label><element-citation publication-type="other" id="sref1a"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention</collab></person-group><article-title>Defining adult overweight and obesity</article-title><comment>Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/bmi/adult-calculator/bmi-categories.html?CDC_AAref_Val=https://www.cdc.gov/obesity/basics/adult-defining.html" id="intref0040">https://www.cdc.gov/bmi/adult-calculator/bmi-categories.html?CDC_AAref_Val=https://www.cdc.gov/obesity/basics/adult-defining.html</ext-link></element-citation></ref><ref id="bib29"><label>28</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Cruz</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Popov</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pawankar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Annesi-Maesano</surname><given-names>I.</given-names></name><name name-style="western"><surname>Fokkens</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kemp</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA<sup>2</sup>LEN</article-title><source>Allergy</source><volume>62</volume><issue>suppl&#160;84</issue><year>2007</year><fpage>1</fpage><lpage>41</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1398-9995.2007.01551.x</pub-id><pub-id pub-id-type="pmid">17924930</pub-id></element-citation></ref><ref id="bib30"><label>29</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Kouis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lemonaris</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xenophontos</surname><given-names>E.</given-names></name><name name-style="western"><surname>Panayiotou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yiallouros</surname><given-names>P.K.</given-names></name></person-group><article-title>The impact of COVID-19 lockdown measures on symptoms control in children with asthma: a systematic review and meta-analysis of observational cohort studies</article-title><source>Pediatr Pulmonol</source><volume>58</volume><year>2023</year><fpage>3213</fpage><lpage>3226</lpage><pub-id pub-id-type="pmid">37606188</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ppul.26646</pub-id></element-citation></ref><ref id="bib31"><label>30</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>A.H.Y.</given-names></name><name name-style="western"><surname>Tomlin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>J.</given-names></name><name name-style="western"><surname>Beyene</surname><given-names>K.A.</given-names></name></person-group><article-title>Effect of the COVID-19 pandemic on asthma exacerbations in New Zealand: an interrupted time series analysis</article-title><source>J Allergy Clin Immunol Glob</source><volume>2</volume><year>2023</year><object-id pub-id-type="publisher-id">100157</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacig.2023.100157</pub-id><pub-id pub-id-type="pmcid">PMC10509955</pub-id><pub-id pub-id-type="pmid">37781646</pub-id></element-citation></ref><ref id="bib32"><label>31</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Quint</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Sheikh</surname><given-names>A.</given-names></name></person-group><article-title>Impact of COVID-19 pandemic on asthma exacerbations: retrospective cohort study of over 500,000 patients in a national English primary care database</article-title><source>Lancet Reg Health Eur</source><volume>19</volume><year>2022</year><object-id pub-id-type="publisher-id">100428</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lanepe.2022.100428</pub-id><pub-id pub-id-type="pmcid">PMC9213032</pub-id><pub-id pub-id-type="pmid">35756853</pub-id></element-citation></ref><ref id="bib33"><label>32</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gates</surname><given-names>A.</given-names></name><name name-style="western"><surname>Radhakrishnan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mirabelli</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Flanders</surname><given-names>W.D.</given-names></name><name name-style="western"><surname>Sircar</surname><given-names>K.</given-names></name></person-group><article-title>Changes in asthma emergency department visits in the United States during the COVID-19 pandemic</article-title><source>J Asthma</source><volume>60</volume><year>2023</year><fpage>1601</fpage><lpage>1607</lpage><pub-id pub-id-type="pmid">36608267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/02770903.2023.2165445</pub-id><pub-id pub-id-type="pmcid">PMC10293019</pub-id></element-citation></ref><ref id="bib34"><label>33</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Salciccioli</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>She</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tulchinsky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rockhold</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cardet</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Israel</surname><given-names>E.</given-names></name></person-group><article-title>Effect of COVID-19 on asthma exacerbation</article-title><source>J Allergy Clin Immunol Pract</source><volume>9</volume><year>2021</year><fpage>2896</fpage><lpage>2899.e1</lpage><pub-id pub-id-type="pmid">33940216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaip.2021.04.038</pub-id><pub-id pub-id-type="pmcid">PMC8086260</pub-id></element-citation></ref><ref id="bib35"><label>34</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Kenyon</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Henrickson</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Bryant-Stephens</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Zorc</surname><given-names>J.J.</given-names></name></person-group><article-title>Initial effects of the COVID-19 pandemic on pediatric asthma emergency department utilization</article-title><source>J Allergy Clin Immunol Pract</source><volume>8</volume><year>2020</year><fpage>2774</fpage><lpage>2776.e1</lpage><pub-id pub-id-type="pmid">32522565</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaip.2020.05.045</pub-id><pub-id pub-id-type="pmcid">PMC7483361</pub-id></element-citation></ref><ref id="bib36"><label>35</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Papadopoulos</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Mathioudakis</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Custovic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Deschildre</surname><given-names>A.</given-names></name><name name-style="western"><surname>Phipatanakul</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Childhood asthma outcomes during the COVID-19 pandemic: findings from the PeARL multi-national cohort</article-title><source>Allergy</source><volume>76</volume><year>2021</year><fpage>1765</fpage><lpage>1775</lpage><pub-id pub-id-type="pmid">33608919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/all.14787</pub-id><pub-id pub-id-type="pmcid">PMC8013557</pub-id></element-citation></ref><ref id="bib37"><label>36</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Sayed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Diwadkar</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Dudley</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dvorin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kenyon</surname><given-names>C.C.</given-names></name><etal/></person-group><article-title>COVID-19 pandemic&#8211;related reductions in pediatric asthma exacerbations corresponded with an overall decrease in respiratory viral infections</article-title><source>J Allergy Clin Immunol Pract</source><volume>10</volume><year>2022</year><fpage>91</fpage><lpage>99.e12</lpage><pub-id pub-id-type="pmid">34785388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaip.2021.10.067</pub-id><pub-id pub-id-type="pmcid">PMC8590625</pub-id></element-citation></ref><ref id="bib38"><label>37</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Simoneau</surname><given-names>T.</given-names></name><name name-style="western"><surname>Greco</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Hammond</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gaffin</surname><given-names>J.M.</given-names></name></person-group><article-title>Impact of the COVID-19 pandemic on pediatric emergency department use for asthma</article-title><source>Ann Am Thorac Soc</source><volume>18</volume><year>2021</year><fpage>717</fpage><lpage>719</lpage><pub-id pub-id-type="pmid">33272107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1513/AnnalsATS.202007-765RL</pub-id><pub-id pub-id-type="pmcid">PMC8009002</pub-id></element-citation></ref><ref id="bib39"><label>38</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Taquechel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Diwadkar</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Sayed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dudley</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Grundmeier</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Kenyon</surname><given-names>C.C.</given-names></name><etal/></person-group><article-title>Pediatric asthma health care utilization, viral testing, and air pollution changes during the COVID-19 pandemic</article-title><source>J Allergy Clin Immunol Pract</source><volume>8</volume><year>2020</year><fpage>3378</fpage><lpage>3387.e11</lpage><pub-id pub-id-type="pmid">32827728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaip.2020.07.057</pub-id><pub-id pub-id-type="pmcid">PMC7438361</pub-id></element-citation></ref><ref id="bib40"><label>39</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Thomson</surname><given-names>N.C.</given-names></name></person-group><article-title>The role of smoking in asthma and chronic obstructive pulmonary disease overlap</article-title><source>Immunol Allergy Clin North Am</source><volume>42</volume><year>2022</year><fpage>615</fpage><lpage>630</lpage><pub-id pub-id-type="pmid">35965049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.iac.2022.03.004</pub-id></element-citation></ref><ref id="bib41"><label>40</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Kuruvilla</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>F.E.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>G.B.</given-names></name></person-group><article-title>Understanding asthma phenotypes, endotypes, and mechanisms of disease</article-title><source>Clin Rev Allergy Immunol</source><volume>56</volume><year>2019</year><fpage>219</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">30206782</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12016-018-8712-1</pub-id><pub-id pub-id-type="pmcid">PMC6411459</pub-id></element-citation></ref><ref id="bib42"><label>41</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Lefaudeux</surname><given-names>D.</given-names></name><name name-style="western"><surname>De Meulder</surname><given-names>B.</given-names></name><name name-style="western"><surname>Loza</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Peffer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baribaud</surname><given-names>F.</given-names></name><etal/></person-group><article-title>U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics</article-title><source>J Allergy Clin Immunol</source><volume>139</volume><year>2017</year><fpage>1797</fpage><lpage>1807</lpage><pub-id pub-id-type="pmid">27773852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaci.2016.08.048</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><title>Supplementary data</title><p id="p0185">
<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Supplementary Tables</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc2" position="float" orientation="portrait"><caption><title>Supplementary data</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc2.docx" position="float" orientation="portrait"/></supplementary-material>
</p></sec><ack id="ack0010"><p id="p0180">We thank Sam Chiu, Victoria Rautman, and Mario Gallone from the University of Pennsylvania Data Analytics Center and Penn Data Store for extracting the EHR data used for this project.</p></ack></back></article></pmc-articleset>